F-Prime Capital

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery specifically for diverse and underserved populations that have historically been underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample and bioinformatics platform, utilizing advanced algorithms and innovative analyses to facilitate genomic discoveries. Through its world-class clinical network, the company aims to identify patients at risk for severe multi-inflammatory syndromes or infections, ultimately working to develop new tests, treatments, and cures that enhance healthcare outcomes for all.

Bluebird Kids Health is a pediatric healthcare provider that aims to build a healthier future for children. It offers a value-based care model, delivering comprehensive, evidence-based care tailored to each family's needs. Services include nutrition support, sleep training, treatments for common ailments like rashes and viruses, all aimed at reducing medical costs and providing personalized care. The company is also developing a proprietary technology platform, enhanced by AI, to proactively manage and coordinate treatment, further simplifying the experience for its clinical team.

Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.

Founded in 2014 by Stanford University Biodesign Fellows collaborating with leading urologists, Zenflow develops a novel spring device to alleviate permanent benign prostatic hyperplasia (BPH) symptoms in men. Its minimally invasive solution preserves natural anatomy and improves patient experience.

Based on our deep science and focused on patients in need.

Shift Bioscience employs simulation-guided techniques to identify safer gene factors for cellular rejuvenation, aiming to develop a drug family that treats multiple age-related diseases. Its high-throughput aging biomarker enables accurate cell simulations, with the goal of making full health in old age accessible via prescription.

Spry is a digital health platform that enables movement health professionals to collect and analyze patient data in real time. By leveraging machine learning and artificial intelligence, the platform provides personalized protocols based on evidence-based practices and standards of care. This allows practitioners and owners of physical therapy centers to effectively manage both clinical and administrative functions, enhancing the quality of patient care and operational efficiency.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.

Expressable is an online speech therapy practice dedicated to enhancing communication for individuals with speech and language disorders. It employs a parent-focused care model that integrates technology and educational resources, allowing families to incorporate speech therapy techniques into their daily routines. The platform offers a range of services, including support for accent modification, aphasia, apraxia of speech, autism spectrum disorder, and various language disorders. By providing tailored weekly practice activities, Expressable aims to improve speech and language outcomes for both children and adults, ensuring a more effective and accessible therapy experience.

Metsera is a clinical-stage biopharmaceutical company specializing in developing innovative therapies for obesity and metabolic conditions. It focuses on advancing oral and injectable treatments, integrating proprietary health technology tools for personalized care.

HiLabs is a developer of a healthcare data mining platform that aims to enhance data-driven decision-making within healthcare organizations. By leveraging artificial intelligence, HiLabs empowers employees to explore their data intuitively, uncover novel insights, and interact with data visualizations. The platform allows users to customize dashboards and generate new attributes, thus enhancing their ability to understand and utilize client health data effectively. HiLabs recognizes that healthcare providers possess vital domain knowledge but often lack the necessary tools to extract meaningful insights from their data. Through its innovative solutions, HiLabs bridges this gap, enabling healthcare organizations to harness their data more efficiently and improve overall decision-making processes.

Nocion Therapeutics is a biopharmaceutical company developing novel therapies called 'nocions' that selectively target actively firing nociceptors to provide relief for serious conditions such as cough, itch, pain, and inflammation.

Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. Its mission is to provide safe, effective, evidence-based, and affordable therapies for treating life-threatening complications of pregnancy.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

OnCusp Therapeutics is a biopharmaceutical company dedicated to accelerating oncology medication innovation globally. It focuses on translating preclinical drug candidates into clinical proof-of-concept stage and advancing them for rapid global early clinical development.

PlasmaGen Biosciences Pvt. Ltd., established in 2010 and based in Bengaluru, India, is a biopharmaceutical company specializing in plasma protein therapies. The company manufactures a range of products including PlasmaGlob and AlbuMax, brands of Normal Human Immunoglobulin for Intravenous use, PlasmaRho-D I.V. for Rh immunization suppression, PlasmaRAB for rabies infection prophylaxis, PlasmaHep for hepatitis B exposure, VerBumin for conditions like hypovolemic shock and burns, and Gammafact-VIII. These products cater to various medical fields such as hematology, oncology, immunology, pediatrics, rheumatology, dermatology, and neurology. The company serves clinicians, medical practitioners, corporate hospitals, and government institutions.

Shinobi Therapeutics is a biotechnology company dedicated to developing innovative cell therapies that utilize hypoimmune CD8αβ induced pluripotent stem cells (iPS-T cells) to enhance cancer treatment and address other diseases. The company's advanced immune evasion technology aims to improve the effectiveness and accessibility of these therapies, ultimately reducing costs and enhancing patient outcomes. By focusing on durable responses and the potential for redosing, Shinobi Therapeutics strives to provide the healthcare industry with comprehensive immune therapies that can address a range of diseases, including cancer and genetic disorders.

ARTBIO is a biotechnology company developing a new class of alpha radioligand medicines for cancer treatment. It focuses on radioligand therapy, delivering alpha or beta emitters to target and destroy cancer cells.

T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.

Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.

Doceree is a healthcare marketing technology company that provides a platform and solutions to help pharmaceutical and healthcare brands reach healthcare professionals. Its programmatic platform supports physician engagement and targeted advertising across physician networks, medical journals, telemedicine platforms, and relevant digital channels, delivering compliant, scalable messages. The platform uses artificial intelligence, data segmentation, and analytics to identify target healthcare professionals and optimize reach across global digital ecosystems. Doceree serves pharmaceutical brands, medical device brands, consumer health brands, hospitals, and media agencies, enabling access to physician-only environments and enabling compliant engagement at scale.

Better Life Partners Inc. is a healthcare company based in Hanover, New Hampshire, dedicated to providing comprehensive support for individuals struggling with opioid use disorder in the United States. Established in 2018, the company offers a range of services, including medication-assisted treatment, counseling, peer coaching, and group sessions. Better Life Partners focuses on delivering personalized healthcare to vulnerable populations, utilizing technology to create customizable care plans that ensure effective and reliable service delivery. By integrating medical and behavioral healthcare, the company addresses the needs of those affected by addiction, facilitating their recovery through a combination of telehealth, community-based support, and innovative care approaches. With additional offices across New Hampshire, Better Life Partners aims to make a meaningful impact on the lives of individuals seeking to overcome substance abuse challenges.

K36 Therapeutics develops small molecule therapeutics for cancer treatment. It translates epigenetic modulation of oncogenic pathways into small molecule therapies.

ARTBIO is a biotechnology company developing a new class of alpha radioligand medicines for cancer treatment. It focuses on radioligand therapy, delivering alpha or beta emitters to target and destroy cancer cells.

Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. Its mission is to provide safe, effective, evidence-based, and affordable therapies for treating life-threatening complications of pregnancy.

Founded in 2017, 1upHealth operates a health data aggregation platform that securely centralizes patient records from various electronic medical systems. Its platform enables patients to control and share their consolidated digital health record with providers, while also allowing developers to access clinical data from connected clinics and hospitals.

Zus Health is a healthcare technology company founded in 2020 by Jonathan Bush, based in Watertown, Massachusetts. It specializes in developing a healthcare data platform that accelerates the creation of digital health solutions. The platform uniquely integrates health and non-health information, allowing healthcare professionals to gain a comprehensive understanding of patients while sharing clinical and non-clinical data without requiring the same applications. By removing traditional barriers, Zus Health empowers a new generation of healthcare builders to design technologies and services that are more affordable and customizable, aiming to enhance the overall healthcare experience.

SpectrumAi is a digital health company focused on enhancing Autism care by increasing access to high-quality Applied Behavior Analysis (ABA) therapy for children globally. By collaborating with industry experts in technology and healthcare, as well as clinical leaders, parents, and payers, SpectrumAi aims to modernize the delivery of autism care. The company's innovative healthcare technology offers objective data, meaningful insights, and actionable recommendations, all designed to support patients in achieving optimal outcomes. These outcomes include fostering independent living, building meaningful relationships, pursuing lifelong vocational goals, and promoting self-advocacy. Through its efforts, SpectrumAi seeks to transform the landscape of autism treatment and improve the quality of life for individuals on the spectrum.

Cadence Neuroscience develops implantable medical device therapies for epilepsy, central pain, and other neurological disorders. Founded in 2017 and based in Redmond, Washington, the company pursues core technology developed at Mayo Clinic that is being evaluated clinically. The device detects brain signals and delivers electrical stimulation to modulate neural circuits, enabling personalized brain stimulation to improve seizure control relative to existing protocols.

NOCD Inc. is a Chicago-based company founded in 2014 that specializes in developing a mobile application aimed at assisting individuals with obsessive-compulsive disorder (OCD). The platform connects users to licensed therapists who specialize in OCD through face-to-face video therapy sessions. Utilizing cognitive behavioral therapy techniques, the application guides users in self-treatment and monitoring of their symptoms, offering tools for exposure and response prevention exercises. In addition to therapy sessions, NOCD provides 24/7 support via self-help resources and peer communities, facilitating ongoing care and enabling patients to manage their condition effectively. The company focuses on improving treatment outcomes for OCD through its innovative online platform.

Enzene Biosciences develops cost-effective biosimilars through advanced analytics and state-of-the-art manufacturing. It aims to provide affordable medicines swiftly, utilizing good manufacturing practices (GMP) processes.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Founded in 2012, ABK Biomedical specializes in developing embolotherapeutic products for treating hypervascular tumors. Its primary focus is improving treatment options for patients through innovative microsphere technology.

Founded in 2016, Firefly Health delivers AI-driven virtual-first primary care. Its platform connects patients with healthcare professionals for convenient, continuous care, focusing on common conditions and women's health issues.

Elucidata Corporation, established in 2015 and based in New Delhi, India, specializes in accelerating drug discovery by translating phenotypic screenings into therapeutic strategies. The company's core offering is Polly, a proprietary SaaS platform that transforms drug discovery through curated biomedical molecular data. Polly hosts over 230,000 multi-omic datasets, with around 50,000 new datasets added monthly, and offers exclusive access to curated data ready for machine learning workflows. This platform enables 10x faster identification of therapeutic assets and has facilitated the detection of multiple validated drug targets across immunology, oncology, and metabolomic disorders. Polly supports discovery programs at prominent biopharma companies such as Pfizer, Agios Pharmaceuticals, Genentech, and Yale, with over 35 research partners from premier institutions.

RIGImmune is a biopharmaceutical company dedicated to developing innovative immune-modulating therapies targeting RNA virus diseases and enhancing antitumor immune responses. The company focuses on creating novel treatments aimed at addressing a wide range of conditions associated with viral infections and certain cancers. Its therapeutic candidates are designed to improve treatment outcomes for viral respiratory infections, serving as adjuvants or boosters for healthcare providers. By advancing its research and development efforts, RIGImmune aims to contribute significantly to the treatment landscape for both viral and oncological diseases.

Spry is a digital health platform that enables movement health professionals to collect and analyze patient data in real time. By leveraging machine learning and artificial intelligence, the platform provides personalized protocols based on evidence-based practices and standards of care. This allows practitioners and owners of physical therapy centers to effectively manage both clinical and administrative functions, enhancing the quality of patient care and operational efficiency.

Immuneel Therapeutics specializes in developing innovative cell and gene therapies for cancer treatment. The company focuses on CAR-T cell therapies, which are created by extracting blood cells from patients and genetically engineering healthy immune cells to specifically target malignant cells. This approach allows cancer patients to benefit from advanced cell-based immunotherapies that have the potential to transform their treatment outcomes.

Proximie is a health technology company that enables surgeons worldwide to collaborate remotely using augmented reality, artificial intelligence, and machine learning. Its platform allows surgeons to visually guide complex surgeries, democratizing access to advanced surgical knowledge.

CHARM Therapeutics uses 3D deep learning and advanced drug discovery technologies to develop transformational medicines for diseases that are difficult to treat, aiming to enable clinicians to target undruggable disease targets with novel therapies that offer potentially life-changing efficacy.

SpectrumAi is a digital health company focused on enhancing Autism care by increasing access to high-quality Applied Behavior Analysis (ABA) therapy for children globally. By collaborating with industry experts in technology and healthcare, as well as clinical leaders, parents, and payers, SpectrumAi aims to modernize the delivery of autism care. The company's innovative healthcare technology offers objective data, meaningful insights, and actionable recommendations, all designed to support patients in achieving optimal outcomes. These outcomes include fostering independent living, building meaningful relationships, pursuing lifelong vocational goals, and promoting self-advocacy. Through its efforts, SpectrumAi seeks to transform the landscape of autism treatment and improve the quality of life for individuals on the spectrum.

Doceree is a healthcare marketing technology company that provides a platform and solutions to help pharmaceutical and healthcare brands reach healthcare professionals. Its programmatic platform supports physician engagement and targeted advertising across physician networks, medical journals, telemedicine platforms, and relevant digital channels, delivering compliant, scalable messages. The platform uses artificial intelligence, data segmentation, and analytics to identify target healthcare professionals and optimize reach across global digital ecosystems. Doceree serves pharmaceutical brands, medical device brands, consumer health brands, hospitals, and media agencies, enabling access to physician-only environments and enabling compliant engagement at scale.

Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.

AmplifyMD is a telemedicine platform that connects over 3,300 medical institutions lacking specialty access, often in rural or small regions, with a network of leading specialists. It provides clinical teams and software to streamline virtual care delivery and billing workflows, integrating seamlessly with hospitals' existing EHR systems.

Rialtic operates an open marketplace enterprise platform that equips payers to make accurate healthcare payments. The platform provides a reference source repository, curated material, and payment accuracy technology to improve payment accuracy, contain healthcare costs, adapt to regulatory and policy changes, and support ongoing improvements to claims accuracy.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

Expressable is an online speech therapy practice dedicated to enhancing communication for individuals with speech and language disorders. It employs a parent-focused care model that integrates technology and educational resources, allowing families to incorporate speech therapy techniques into their daily routines. The platform offers a range of services, including support for accent modification, aphasia, apraxia of speech, autism spectrum disorder, and various language disorders. By providing tailored weekly practice activities, Expressable aims to improve speech and language outcomes for both children and adults, ensuring a more effective and accessible therapy experience.

K36 Therapeutics develops small molecule therapeutics for cancer treatment. It translates epigenetic modulation of oncogenic pathways into small molecule therapies.

AviadoBio focuses on developing transformative gene therapies for devastating neurodegenerative disorders such as frontotemporal dementia and amyotrophic lateral sclerosis. The company's platform combines proprietary technologies with a deep understanding of the brain to deliver effective treatments.

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery specifically for diverse and underserved populations that have historically been underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample and bioinformatics platform, utilizing advanced algorithms and innovative analyses to facilitate genomic discoveries. Through its world-class clinical network, the company aims to identify patients at risk for severe multi-inflammatory syndromes or infections, ultimately working to develop new tests, treatments, and cures that enhance healthcare outcomes for all.

AppliedVR is a Los Angeles‑based company that develops virtual reality therapeutic devices for pain and anxiety management in healthcare settings. Founded in 2013, it partners with institutions such as Cedars‑Sinai and Children’s Hospital Los Angeles to deliver its VR platform in hospitals, surgery centers, and exam rooms across the United States. The company’s flagship product, EaseVRx, is the first VR‑based prescription therapeutic to receive FDA Breakthrough Device Designation; it combines cognitive behavioral therapy and mindfulness to help patients alter pain perception and build coping skills. EaseVRx is self‑administered at home, enabling remote care and improving access, equity, and efficiency in chronic pain treatment. AppliedVR’s clinically validated, on‑demand platform supports both acute and chronic pain, promotes non‑drug pain management, and assists clinicians in achieving better long‑term patient outcomes.

Notable is an artificial intelligence platform for healthcare operations that automates administrative and operational tasks within health systems, clinics, and other care settings. The platform handles patient intake, scheduling, prior authorization, documentation, and billing automation, enabling providers and staff to streamline workflows and reduce manual workload for more efficient care delivery. It is deployed at over 10,000 sites of care and automates a million repetitive workflows daily across Registration and Intake, Scheduling and Referrals, Assistant, Authorizations, Care Gap Closure, and HCC Chart Review, leading to faster patient processing, improved care coordination, and stronger financial performance for healthcare organizations.

Patina is a healthcare company reinventing primary care for older adults by delivering a human, personalized, on-demand care model designed to improve the healthcare and aging experience for seniors and their families. The approach centers on the specific needs and values of aging individuals, offering flexible access to care and enabling families and loved ones to participate as part of the care team. By focusing on dignity in aging and a coordinated, person-centered experience, Patina aims to align medical care with daily living and the goals of aging adults.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

NOCD Inc. is a Chicago-based company founded in 2014 that specializes in developing a mobile application aimed at assisting individuals with obsessive-compulsive disorder (OCD). The platform connects users to licensed therapists who specialize in OCD through face-to-face video therapy sessions. Utilizing cognitive behavioral therapy techniques, the application guides users in self-treatment and monitoring of their symptoms, offering tools for exposure and response prevention exercises. In addition to therapy sessions, NOCD provides 24/7 support via self-help resources and peer communities, facilitating ongoing care and enabling patients to manage their condition effectively. The company focuses on improving treatment outcomes for OCD through its innovative online platform.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.

GYENNO Technologies is a digital health company developing medical devices for people with disabilities. GYENNO's products include GYENNO spoon, which helps people with hand tremors eat without stress, and the GYENNO matrix, a wearable motion and gait quantitative evaluation system for Parkinson's disease.

Founded in 2013, Oviva specializes in digital behavior change programs for managing type 2 diabetes and obesity. Their platform combines smartphone apps and learning portals, supported by dietitian-led coaching, enabling patients to improve their health remotely and reducing healthcare system costs.

SonderMind is a Denver-based digital health company established in 2017, specializing in accessible and approachable mental health services. It operates an online platform that connects individuals with a network of licensed therapists, offering a range of services including video telehealth and in-person sessions. SonderMind focuses on various mental health conditions such as anxiety, depression, ADHD, and PTSD, among others. The company aims to streamline the process of finding and accessing mental health care, ensuring a good match between clients and therapists, while also supporting therapists by handling administrative and billing tasks.

Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.

Castor is an international health-tech company that provides a cloud-based clinical data platform designed to streamline the clinical trial process for researchers globally. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries, supporting more than 4,000 studies across diverse therapeutic areas, including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Castor's platform facilitates the collection and analysis of extensive data from both traditional and remote trials, having reached significant milestones such as 180 million data points and 2 million enrolled patients. The company's mission is to make research data reusable, thereby enabling AI-driven clinical trials and enhancing the overall impact of data within the medical research community.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.

Zus Health is a healthcare technology company founded in 2020 by Jonathan Bush, based in Watertown, Massachusetts. It specializes in developing a healthcare data platform that accelerates the creation of digital health solutions. The platform uniquely integrates health and non-health information, allowing healthcare professionals to gain a comprehensive understanding of patients while sharing clinical and non-clinical data without requiring the same applications. By removing traditional barriers, Zus Health empowers a new generation of healthcare builders to design technologies and services that are more affordable and customizable, aiming to enhance the overall healthcare experience.

Protenus, Inc. is a healthcare compliance analytics company based in Baltimore, Maryland, which was founded in 2014. The company specializes in an AI-driven platform designed to audit access to patient records across health systems in the United States. Protenus' technology identifies risks such as inappropriate access to patient data and the misuse of controlled substances by healthcare staff. By automating the detection of policy violations and other anomalous behaviors, the platform supports healthcare organizations in protecting patient privacy and reducing operational risks. Protenus is recognized for its innovation and commitment to fostering safe patient outcomes while enhancing the reputation of healthcare providers. The company has received accolades such as being named one of America's Best Startup Employers by Forbes and recognized as a Great Place to Work.

Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies for muscular and central nervous system diseases. The company uses an AAV vector design platform built on synthetic and systems biology, high-throughput screening, and tissue- and single-cell-resolution analyses to create vectors with improved properties. It leverages sequencing, artificial intelligence, and structural modeling to enable rational design of therapies. Headquartered in Waltham, Massachusetts, Affinia Therapeutics was founded in 2019 and targets diseases with significant unmet needs in muscle and CNS.

Pediatrix Therapeutics specializes in pediatric pharmaceuticals, focusing on developing and distributing effective, clinically proven children's medicines. Its mission is to provide high-quality, affordable treatment options for Chinese children and families.

Proximie is a health technology company that enables surgeons worldwide to collaborate remotely using augmented reality, artificial intelligence, and machine learning. Its platform allows surgeons to visually guide complex surgeries, democratizing access to advanced surgical knowledge.

Founded in 2017, 1upHealth operates a health data aggregation platform that securely centralizes patient records from various electronic medical systems. Its platform enables patients to control and share their consolidated digital health record with providers, while also allowing developers to access clinical data from connected clinics and hospitals.

Founded in 2014 by Stanford University Biodesign Fellows collaborating with leading urologists, Zenflow develops a novel spring device to alleviate permanent benign prostatic hyperplasia (BPH) symptoms in men. Its minimally invasive solution preserves natural anatomy and improves patient experience.

Founded in 2016, Firefly Health delivers AI-driven virtual-first primary care. Its platform connects patients with healthcare professionals for convenient, continuous care, focusing on common conditions and women's health issues.

AppliedVR is a Los Angeles‑based company that develops virtual reality therapeutic devices for pain and anxiety management in healthcare settings. Founded in 2013, it partners with institutions such as Cedars‑Sinai and Children’s Hospital Los Angeles to deliver its VR platform in hospitals, surgery centers, and exam rooms across the United States. The company’s flagship product, EaseVRx, is the first VR‑based prescription therapeutic to receive FDA Breakthrough Device Designation; it combines cognitive behavioral therapy and mindfulness to help patients alter pain perception and build coping skills. EaseVRx is self‑administered at home, enabling remote care and improving access, equity, and efficiency in chronic pain treatment. AppliedVR’s clinically validated, on‑demand platform supports both acute and chronic pain, promotes non‑drug pain management, and assists clinicians in achieving better long‑term patient outcomes.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Yisheng Biopharma Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and marketing of immuno-oncology products and vaccines. Founded in 2002 and headquartered in Beijing, the company operates in China, the United States, Cambodia, and Singapore. Yisheng Biopharma utilizes its novel PIKA immunomodulating technology to enhance immune responses against cancers and infectious diseases. Key products under development include YS-ON-001, an investigational therapy aimed at treating advanced solid tumors, as well as YS-HBV-001, a vaccine for hepatitis B, and a PIKA-based rabies vaccine designed for rapid protection against rabies infection. The company's innovative approach targets multiple immune pathways to improve treatment outcomes.

Cohort, Inc. is a software company focused on enhancing chronic care management and clinical trial processes. Based in New York with an additional office in San Francisco, the company utilizes clinical artificial intelligence and natural language processing to analyze electronic health records. This analysis includes evaluating diagnostics, medications, and clinical notes to provide context relevant to specific patients and their conditions. Cohort’s software streamlines the identification and enrollment of eligible patients, generates tailored care plans, and automates compliance and billing tasks. The company’s solutions are designed to enable Primary Care Providers to improve the scale, efficiency, and outcomes of their Chronic Care Management programs while facilitating clinical trial identification and enrollment.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

Hurdle Health, Inc., established in 2020 and based in Washington, D.C., specializes in culturally intentional mental health services. The company operates a digital platform that connects diverse individuals, couples, and families with appropriate therapists, offering a suite of teletherapy services and self-mastery tools. Hurdle's approach is tailored to meet the unique needs of underserved populations, providing culturally responsive care for a wide range of stressors. The platform aims to create a safe and understanding space for patients, focusing on serving the BIPOC community and other minority groups.

Metcela is a clinical-stage biotechnology company based in Kawasaki, Japan, developing fibroblast-based therapies for heart disease. Its approach uses VCAM-1–positive cardiac fibroblasts derived from a patient’s own heart to repair damaged tissue and reestablish a supportive microenvironment, rather than replacing cells. The lead program, MTC001, aims to restore heart function by promoting natural healing in preclinical studies. Metcela was founded in 2016.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

WellAir Group Limited, founded in 2012 and based in Dublin, Ireland, specializes in designing and manufacturing portable air disinfection units and HVAC air purification devices. The company aims to improve indoor air quality by eliminating airborne pollutants and pathogens, including viruses, bacteria, allergens, and mold. Its products, marketed under the Novaerus and Plasma-Air brands, serve a variety of sectors such as healthcare, senior living, education, and industry. WellAir's offerings include medical-grade air disinfection units that deactivate airborne pathogens and neutralize volatile organic compounds, as well as HVAC systems utilizing plasma-generated bipolar ionization to reduce particulate matter and odors. Additionally, WellAir develops sensors and a web-based monitoring portal that tracks outdoor air pollution and other environmental factors, contributing to safer indoor environments and promoting public health.

Founded in 2018, Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. The company aims to reprogram cells in the body or replace damaged ones to treat a broad range of diseases, with a pipeline including SC291, SC262, SC255, UP421, and other candidates across therapeutic areas like oncology, diabetes, autoimmune disorders, and CNS.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

PatientPing, Inc. is a health technology company that has developed a national care coordination network aimed at enhancing communication among healthcare providers. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers real-time notifications and care guidelines to various healthcare professionals, including physicians, nurses, case managers, and care coordinators. This network spans hospitals, emergency departments, accountable care organizations, physician practices, skilled nursing facilities, home health agencies, and payers. PatientPing's platform includes a tool called Spotlights, which leverages real-time data to analyze utilization and performance trends in patient care. By improving information sharing among care teams, PatientPing facilitates higher quality, cost-effective care, ultimately aiming to enhance patient outcomes and experiences. The company also maintains a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC.

NodThera is a UK-based biotechnology company focused on developing novel inhibitors of the NLRP3 inflammasome for treating inflammatory and neuroinflammatory diseases. Established in 2016, it operates laboratories in Little Chesterford (UK) and Seattle (US), with corporate offices in Lexington (US). The company's primary research involves inflammasomes, multi-protein complexes targeting conditions such as arthritis, atherosclerosis, Alzheimer's disease, diabetes, and certain cancers.

Founded in 2016, Owkin is a French-American startup that uses artificial intelligence to enhance medical research. It develops machine learning tools to understand complex biology, identify new treatments, de-risk clinical trials, and develop diagnostics. Owkin's focus is improving drug discovery processes and patient outcomes.

Avalyn Pharma is a biopharmaceutical company focused on developing therapies for severe respiratory diseases, notably idiopathic pulmonary fibrosis (IPF). Established in 2011, the company is headquartered in Seattle, Washington.

SonderMind is a Denver-based digital health company established in 2017, specializing in accessible and approachable mental health services. It operates an online platform that connects individuals with a network of licensed therapists, offering a range of services including video telehealth and in-person sessions. SonderMind focuses on various mental health conditions such as anxiety, depression, ADHD, and PTSD, among others. The company aims to streamline the process of finding and accessing mental health care, ensuring a good match between clients and therapists, while also supporting therapists by handling administrative and billing tasks.

Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies for muscular and central nervous system diseases. The company uses an AAV vector design platform built on synthetic and systems biology, high-throughput screening, and tissue- and single-cell-resolution analyses to create vectors with improved properties. It leverages sequencing, artificial intelligence, and structural modeling to enable rational design of therapies. Headquartered in Waltham, Massachusetts, Affinia Therapeutics was founded in 2019 and targets diseases with significant unmet needs in muscle and CNS.

B-One Ortho Corp. is a manufacturer of orthopedic healthcare solutions, specializing in artificial joints that facilitate joint replacement surgeries. Founded in 2015 and headquartered in Cedar Knolls, New Jersey, the company also maintains offices in Shanghai and Suzhou, China. Its notable products include the B-One total hip system, which features advanced coating technology and instrumentation, as well as the Juveno bone-conserving femoral prosthesis and primary acetabular systems. These innovations aim to enhance the effectiveness of hip and knee arthroplasty, ultimately helping patients regain their mobility and improve their quality of life.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

WelbeHealth serves frail seniors through its PACE (Program of All-Inclusive Care for the Elderly) model, providing comprehensive medical and social care. This enables participants to live better, longer, and more independently. The company coordinates various aspects of care, including medical appointments, therapy sessions, transportation, meals, and personal care services.

Founded in 2013, Oviva specializes in digital behavior change programs for managing type 2 diabetes and obesity. Their platform combines smartphone apps and learning portals, supported by dietitian-led coaching, enabling patients to improve their health remotely and reducing healthcare system costs.

Adagene is a clinical-stage biotechnology company focused on developing immuno-oncology antibodies targeting novel epitopes. It employs its proprietary Smart Antibody Technology to enhance success rates, expedite time to market, and reduce development costs for therapeutic antibodies.

AviadoBio focuses on developing transformative gene therapies for devastating neurodegenerative disorders such as frontotemporal dementia and amyotrophic lateral sclerosis. The company's platform combines proprietary technologies with a deep understanding of the brain to deliver effective treatments.

Immuneel Therapeutics specializes in developing innovative cell and gene therapies for cancer treatment. The company focuses on CAR-T cell therapies, which are created by extracting blood cells from patients and genetically engineering healthy immune cells to specifically target malignant cells. This approach allows cancer patients to benefit from advanced cell-based immunotherapies that have the potential to transform their treatment outcomes.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

Founded in 2014, Medbanks specializes in healthcare data processing services. It develops an oncology database by collecting and analyzing clinical information from hospitals.

Wellframe Inc. is a Boston-based company that specializes in digital care management and health advocacy solutions. Founded in 2011, it partners with health plans across the country to enhance the relationship between healthcare providers and members. Wellframe's offerings include a mobile application that facilitates daily health reporting, a care team dashboard to prioritize patient needs, and an array of communication tools for two-way messaging. The company also provides comprehensive operational services, such as implementation support, recruiting, and analytics. Additionally, Wellframe's platform employs real-time data and artificial intelligence to deliver personalized care protocols, enabling caregivers to monitor patient status effectively and identify when intervention is necessary. By focusing on mobile patient engagement and care management, Wellframe aims to improve health outcomes and empower individuals in managing their health.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.